Investment analysts at StockNews.com began coverage on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE – Get Rating) in a research report issued on Sunday. The brokerage set a “hold” rating on the stock.
Zynerba Pharmaceuticals Stock Down 2.0 %
Shares of NASDAQ:ZYNE opened at $0.44 on Friday. Zynerba Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $2.28. The stock has a market cap of $20.13 million, a price-to-earnings ratio of -0.51 and a beta of 1.74. The business has a 50-day moving average price of $0.54 and a 200-day moving average price of $0.66.
Institutional Investors Weigh In On Zynerba Pharmaceuticals
A number of large investors have recently modified their holdings of ZYNE. Cetera Advisor Networks LLC purchased a new position in Zynerba Pharmaceuticals during the second quarter worth about $28,000. Verition Fund Management LLC purchased a new position in shares of Zynerba Pharmaceuticals in the second quarter valued at approximately $35,000. Jane Street Group LLC acquired a new position in shares of Zynerba Pharmaceuticals in the third quarter worth $46,000. UBS Group AG raised its holdings in shares of Zynerba Pharmaceuticals by 145.2% in the 1st quarter. UBS Group AG now owns 27,621 shares of the company’s stock valued at $56,000 after purchasing an additional 16,357 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Zynerba Pharmaceuticals in the third quarter valued at $90,000. Hedge funds and other institutional investors own 23.82% of the company’s stock.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery.
- Get a free copy of the StockNews.com research report on Zynerba Pharmaceuticals (ZYNE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.